RESUMEN
Despite significant advances in understanding acute respiratory distress syndrome (ARDS), mortality rates remain high. The appropriate use of adjunctive therapies can improve outcomes, particularly for patients with moderate to severe hypoxia. In this review, the authors discuss the evidence basis behind prone positioning, recruitment maneuvers, neuromuscular blocking agents, corticosteroids, pulmonary vasodilators, and extracorporeal membrane oxygenation and considerations for their use in individual patients and specific clinical scenarios. Because the heterogeneity of ARDS poses challenges in finding universally effective treatments, an individualized approach and continued research efforts are crucial for optimizing the utilization of adjunctive therapies and improving patient outcomes.
Asunto(s)
Oxigenación por Membrana Extracorpórea , Síndrome de Dificultad Respiratoria , Humanos , Síndrome de Dificultad Respiratoria/terapiaAsunto(s)
Enfermedades Pulmonares Obstructivas/etiología , Hipertensión Arterial Pulmonar/fisiopatología , Adulto , Progresión de la Enfermedad , Femenino , Humanos , Pulmón/diagnóstico por imagen , Pulmón/patología , Pulmón/fisiopatología , Enfermedades Pulmonares Obstructivas/diagnóstico por imagen , Enfermedades Pulmonares Obstructivas/patología , Enfermedades Pulmonares Obstructivas/fisiopatología , Masculino , Persona de Mediana Edad , Hipertensión Arterial Pulmonar/diagnóstico por imagen , Hipertensión Arterial Pulmonar/patología , Pruebas de Función Respiratoria , Estudios Retrospectivos , Tomografía Computarizada por Rayos XRESUMEN
Amiodarone is an antiarrhythmic agent used primarily to treat atrial and ventricular arrhythmias. However, the drug also has many adverse effects, including pulmonary toxicity, and a wide range of pulmonary diseases have been reported. Amiodarone-induced eosinophilic pneumonia is a relatively rare adverse effect with an incidence ranging between 5 and 13% [1]. The majority of cases have been diagnosed with lung biopsy, with only one prior reported case diagnosed by bronchoalveolar lavage (BAL) [2]. This report describes the second documented case of amiodarone-induced eosinophilic pneumonia diagnosed by eosinophilia on BAL cytology. In this case, complete cessation of symptoms occurred after discontinuation of amiodarone and treatment with corticosteroids. An updated review of the literature of amiodarone-induced eosinophilic pneumonia is also detailed.
RESUMEN
Primary cardiac tumours are a rare clinical entity that can present with myriad of non-specific cardiopulmonary symptoms. We describe a case of a 61-year-old previously healthy woman who presented with progressive dyspnoea and lower extremity swelling, suggestive of acute left-sided heart failure. Transthoracic echocardiogram revealed a large, 3.7×3.2 cm intracardiac mass resulting in severe mitral valvular dysfunction. The patient underwent surgical resection of the mass, however, negative margins were not obtained, and the tumour quickly returned. Histological and molecular analysis was consistent with the diagnosis of undifferentiated pleomorphic sarcoma with murine double minute 2 (MDM2) amplification. Given the overall grim prognosis, the patient chose to pursue comfort-based care. She died at home 9 months after the initial diagnosis. Here, we provide an updated review of the literature for the classification of undifferentiated pleomorphic cardiac sarcoma and potential treatment modalities.
Asunto(s)
Insuficiencia Cardíaca/diagnóstico por imagen , Neoplasias Cardíacas/patología , Histiocitoma Fibroso Maligno/patología , Sarcoma/patología , Ecocardiografía/métodos , Resultado Fatal , Femenino , Insuficiencia Cardíaca/etiología , Neoplasias Cardíacas/cirugía , Histiocitoma Fibroso Maligno/complicaciones , Histiocitoma Fibroso Maligno/genética , Histiocitoma Fibroso Maligno/cirugía , Humanos , Persona de Mediana Edad , Válvula Mitral/patología , Recurrencia Local de Neoplasia/patología , Proteínas Proto-Oncogénicas c-mdm2/metabolismo , Sarcoma/complicaciones , Sarcoma/genética , Sarcoma/cirugíaRESUMEN
BACKGROUND: (131) I-metaiodobenzylguanidine ((131) I-MIBG) is a targeted radiopharmaceutical for patients with neuroblastoma. Despite its tumor-specific uptake, the treatment with (131) I-MIBG results in whole-body radiation exposure. Our aim was to correlate whole-body radiation dose (WBD) from (131) I-MIBG with tumor response, toxicities, and other clinical factors. METHODS: This retrospective cohort analysis included 213 patients with high-risk neuroblastoma treated with (131) I-MIBG at UCSF Benioff Children's Hospital between 1996 and 2015. WBD was determined from radiation exposure rate measurements. The relationship between WBD ordered tertiles and variables were analyzed using Cochran-Mantel-Haenszel test of trend, Kruskal-Wallis test, and one-way analysis of variance. Correlation between WBD and continuous variables was analyzed using Pearson correlation and Spearman rank correlation. RESULTS: WBD correlated with (131) I-MIBG administered activity, particularly with (131) I-MIBG per kilogram (P < 0.001). Overall response rate did not differ significantly among the three tertiles of WBD. Correlation between response by relative Curie score and WBD was of borderline significance, with patients receiving a lower WBD showing greater reduction in osteomedullary metastases by Curie score (rs = 0.16, P = 0.049). There were no significant ordered trends among tertiles in any toxicity measures (grade 4 neutropenia, thrombocytopenia < 20,000/µl, and grade > 1 hypothyroidism). CONCLUSIONS: This study showed that (131) I-MIBG activity per kilogram correlates with WBD and suggests that activity per kilogram will predict WBD in most patients. Within the range of activities prescribed, there was no correlation between WBD and either response or toxicity. Future studies should evaluate tumor dosimetry, rather than just WBD, as a tool for predicting response following therapy with (131) I-MIBG.